Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Non Operating Income (2016 - 2026)

Amphastar Pharmaceuticals has reported Non Operating Income over the past 13 years, most recently at -$3.7 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 225.11% year-over-year to -$3.7 million; the TTM value through Dec 2025 reached -$16.8 million, down 131.4%, while the annual FY2025 figure was -$16.8 million, 511.65% down from the prior year.
  • Non Operating Income for Q4 2025 was -$3.7 million at Amphastar Pharmaceuticals, up from -$3.8 million in the prior quarter.
  • Over five years, Non Operating Income peaked at $12.9 million in Q3 2021 and troughed at -$12.6 million in Q4 2023.
  • A 5-year average of -$607000.0 and a median of -$1.1 million in 2022 define the central range for Non Operating Income.
  • Biggest five-year swings in Non Operating Income: soared 647.31% in 2023 and later crashed 4699.25% in 2025.
  • Year by year, Non Operating Income stood at $3.2 million in 2021, then fell by 10.74% to $2.9 million in 2022, then tumbled by 543.18% to -$12.6 million in 2023, then soared by 123.36% to $3.0 million in 2024, then crashed by 225.11% to -$3.7 million in 2025.
  • Business Quant data shows Non Operating Income for AMPH at -$3.7 million in Q4 2025, -$3.8 million in Q3 2025, and -$2.8 million in Q2 2025.